KRW 71100.0
(-5.7%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | - | 9.76 Billion | 14.78 Billion | 6.18 Billion | 300.72 Million |
Cost of Revenue | - | - | - | - | - |
Gross Profit | - | 9.76 Billion | 14.78 Billion | 6.18 Billion | 300.72 Million |
Operating Expenses | 28.28 Billion | 27.63 Billion | 25.6 Billion | 33.19 Billion | 54.41 Billion |
Selling, General and Administrative Expenses | 13.81 Billion | 1.93 Billion | 1.6 Billion | 1.43 Billion | 20.16 Billion |
Research and Development Expenses | 14.46 Billion | 11.72 Billion | 12.49 Billion | 13.41 Billion | 31.49 Billion |
Other Expenses | - | 14.1 Million | 3.56 Million | 63.49 Million | - |
Cost and Expenses | 31.33 Billion | 27.63 Billion | 25.6 Billion | 33.19 Billion | 54.41 Billion |
Operating Income | -31.33 Billion | -17.86 Billion | -10.82 Billion | -27.01 Billion | 300.72 Million |
Interest Expense | 1.9 Billion | 2.12 Billion | 834.19 Million | 142.42 Million | 118.54 Million |
Income Tax Expense | 695.84 Million | 464.91 Million | -241.29 Million | -563.13 Million | 443.78 Million |
Earnings before Tax | -36.15 Billion | -19.43 Billion | -15.81 Billion | -27.05 Billion | -54.15 Billion |
Net Income | -36.84 Billion | -19.89 Billion | -15.09 Billion | -23.18 Billion | -50 Billion |
Earnings Per Share Basic | -2401.48 | -1170.19 | -1190.71 | -1954.70 | -4219.58 |
Earnings Per Share Diluted | -2401.33 | -1170.19 | -1190.71 | -1954.70 | -4219.58 |
Weighted Average Shares Outstanding | 15.34 Million | 17 Million | 12.67 Million | 11.86 Million | 11.85 Million |
Weighted Average Shares Outstanding (Diluted) | 15.34 Million | 17 Million | 12.67 Million | 11.86 Million | 11.85 Million |
Gross Margin | - | 1.00 | 1.00 | 1.00 | 1.00 |
EBIT Margin | - | -1.45 | -0.52 | -3.77 | 1.00 |
Profit Margin | - | -2.04 | -1.02 | -3.75 | -166.28 |
EBITDA | -28.63 Billion | -14.28 Billion | -11.77 Billion | -23.64 Billion | -51.38 Billion |
Earnings Before Tax Margin | - | -1.83 | -0.73 | -4.37 | 1.00 |
Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - |
Cost of Revenue | - | - | - | - | - | - |
Gross Profit | - | - | - | - | - | - |
Operating Expenses | -8.63 Billion | -7.61 Billion | 9.34 Billion | 31.33 Billion | 6.63 Billion | 6.82 Billion |
Selling, General and Administrative Expenses | 8.63 Billion | 7.61 Billion | 555.79 Million | - | 521.81 Million | 415.22 Million |
Research and Development Expenses | 4.16 Billion | 3.38 Billion | 4.91 Billion | - | 2.35 Billion | 2.83 Billion |
Other Expenses | -17.27 Billion | -15.23 Billion | 19.37 Million | 49.9 Million | 20.47 Million | 7.68 Million |
Cost and Expenses | -8.63 Billion | -7.61 Billion | 9.34 Billion | 31.33 Billion | 6.63 Billion | 6.82 Billion |
Operating Income | -8.63 Billion | -7.61 Billion | -9.34 Billion | -31.33 Billion | -6.63 Billion | -6.82 Billion |
Interest Expense | - | 244.53 Million | 253.11 Million | 1.9 Billion | 535.75 Million | 580.33 Million |
Income Tax Expense | - | - | 1.45 Billion | 695.84 Million | 525.16 Million | -754.34 Million |
Earnings before Tax | -7.73 Billion | -6.56 Billion | -13.68 Billion | -36.15 Billion | -6.62 Billion | -7.46 Billion |
Net Income | -7.73 Billion | -6.56 Billion | -15.13 Billion | -36.84 Billion | -6.62 Billion | -6.71 Billion |
Earnings Per Share Basic | -445.40 | -384.66 | -899.08 | - | -437.14 | -456.97 |
Earnings Per Share Diluted | -445.40 | -384.66 | -899.08 | - | -437.14 | -456.81 |
Weighted Average Shares Outstanding | 17.37 Million | 17.07 Million | 16.83 Million | 15.34 Million | 15.15 Million | 14.69 Million |
Weighted Average Shares Outstanding (Diluted) | 17.37 Million | 17.07 Million | 16.83 Million | 15.34 Million | 15.15 Million | 14.69 Million |
Gross Margin | - | - | - | - | - | - |
EBIT Margin | - | - | - | - | - | - |
Profit Margin | - | - | - | - | - | - |
EBITDA | -7.73 Billion | -6.56 Billion | -7.87 Billion | - | -5.42 Billion | -4.35 Billion |
Earnings Before Tax Margin | - | - | - | - | - | - |
007460
019685
LH-R
1585
HERB
TCPC